Phase II Study of Chidamide and AK112 for Adults With Advanced Bone and Soft Tissue Sarcoma After First-Line Treatment

What this Trial Is About

Researchers are evaluating the safety and effectiveness of combining Xidabenzamide with AK112 for patients with advanced bone and soft tissue sarcoma who have already tried at least one prior treatment. This Phase II clinical trial aims to find out how well this combination works in controlling disease progression and improving survival and quality of life. The study also monitors safety and how well patients tolerate the treatment. Participants will receive Chidamide Tablets at a dose of 30 mg twice a week taken orally, with at least three days between doses, and AK112 administered once every three weeks intravenously. The treatment continues under the supervision of a doctor who monitors the participants health and adjusts doses if needed. The study includes physical exams and lab tests during the treatment period to evaluate effects and manage any side effects. During the trial, participants will undergo regular tumor assessments every six weeks to measure response to therapy using established evaluation criteria. Researchers will also track overall survival, quality of life, and safety indicators throughout the study. The total participation period includes these ongoing assessments and monitoring until the study ends or the participant stops treatment.

Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma